Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Second-line Nonsquamous NSCLC
NCT03863483Phase 2Unknown
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC). Status: unknown.
02
Drugs
sintilimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03863483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863483.